{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:00:53Z","timestamp":1790215253996,"version":"4.1.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115218","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:53:05Z","timestamp":1785455585000},"page":"115218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Next-generation colon-targeted oral delivery for immune modulation in inflammatory bowel diseases"],"prefix":"10.1016","volume":"398","author":[{"given":"Shang-Wen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Han","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yu","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-Dar","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115218_bb0005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41575-025-01063-x","article-title":"Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response","volume":"22","author":"Solitano","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0010","first-page":"132","article-title":"Global prevalence and incidence of inflammatory bowel disease: a systematic review and meta-analysis of population-based studies","volume":"18","author":"Heydari","year":"2025","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"10.1016\/j.jconrel.2026.115218_bb0015","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819827692","article-title":"Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010","volume":"12","author":"Aniwan","year":"2019","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cgh.2024.06.049","article-title":"The cost of inflammatory bowel disease care: how to make it sustainable","volume":"23","author":"Burisch","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0025","doi-asserted-by":"crossref","first-page":"2400439","DOI":"10.1002\/adtp.202400439","article-title":"Pathophysiology of IBD as a key strategy for polymeric nanoparticle development","volume":"8","author":"Gardey","year":"2025","journal-title":"Adv. Therap."},{"key":"10.1016\/j.jconrel.2026.115218_bb0030","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2544689","article-title":"Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems","volume":"32","author":"Lin","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1039\/D3TB02302H","article-title":"Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances","volume":"12","author":"Hu","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2026.115218_bb0040","article-title":"Colon targeting in rats, dogs and IBD patients with species-independent film coatings","volume":"7","author":"Ferraro","year":"2024","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.jconrel.2026.115218_bb0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jconrel.2024.04.016","article-title":"The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome","volume":"369","author":"McCoubrey","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115218_bb0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jconrel.2020.09.026","article-title":"Recent advances in colon drug delivery systems","volume":"327","author":"Ar\u00e9valo-P\u00e9rez","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115218_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12165272","article-title":"Gastrointestinal transit times in health as determined using ingestible capsule systems: a systematic review","volume":"12","author":"Nandhra","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2026.115218_bb0060","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jconrel.2022.12.029","article-title":"Colonic drug delivery: formulating the next generation of colon-targeted therapeutics","volume":"353","author":"McCoubrey","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115218_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/frmbi.2023.1192316","article-title":"Intestinal and fecal pH in human health","volume":"2","author":"Yamamura","year":"2023","journal-title":"Front. Microbiom."},{"key":"10.1016\/j.jconrel.2026.115218_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114076","article-title":"Clinical translation of advanced colonic drug delivery technologies","volume":"181","author":"Awad","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115218_bb0075","doi-asserted-by":"crossref","first-page":"22208","DOI":"10.1038\/s41598-024-72673-9","article-title":"The gut microbiota of healthy individuals remains resilient in response to the consumption of various dietary fibers","volume":"14","author":"Pihelgas","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115218_bb0080","article-title":"Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease","volume":"19","author":"Zheng","year":"2024","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115218_bb0085","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1039\/D5RA05194K","article-title":"Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems","volume":"16","author":"Mishra","year":"2026","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113903","article-title":"Intestinal retentive delivery system for improved disease therapy","volume":"384","author":"Wu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115218_bb0095","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2147\/DDDT.S461977","article-title":"Nanoparticle-based drug delivery Systems for Inflammatory Bowel Disease Treatment","volume":"18","author":"Gao","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2026.115218_bb0100","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3748\/wjg.v28.i18.1922","article-title":"Novel drug delivery systems for inflammatory bowel disease","volume":"28","author":"Yasmin","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0105","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1023\/A:1011032328064","article-title":"Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa","volume":"18","author":"Lamprecht","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115218_bb0110","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1021\/mp9000926","article-title":"Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa","volume":"6","author":"Tirosh","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115218_bb0115","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.48.4.571","article-title":"Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs","volume":"48","author":"Nugent","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115218_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.actbio.2024.09.007","article-title":"Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy","volume":"188","author":"Long","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115218_bb0125","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/pharmaceutics17020226","article-title":"pH-dependent drug delivery systems for ulcerative colitis treatment","volume":"17","author":"Gvozdeva","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115218_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114466","article-title":"Targeted therapeutics for IBD unraveling the potential of stimulus-responsive nanoparticles","volume":"389","author":"Barros","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115218_bb0135","first-page":"157","article-title":"Nanoparticle-based therapeutics of inflammatory bowel diseases: a narrative review of the current state and prospects","volume":"03","author":"Yang","year":"2020","journal-title":"J. Bio-X Res."},{"key":"10.1016\/j.jconrel.2026.115218_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2026.115218_bb0145","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/pharmaceutics13081183","article-title":"Solid lipid nanoparticles (SLNs): An advanced drug delivery system targeting brain through BBB","volume":"13","author":"Satapathy","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115218_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061593","article-title":"Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review","volume":"15","author":"Viegas","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115218_bb0155","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.2147\/IJN.S466490","article-title":"Research advances of lipid nanoparticles in the treatment of colorectal cancer","volume":"19","author":"Zhang","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115218_bb0160","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2147\/JIR.S304101","article-title":"Recent progress in the diagnosis and precise nanocarrier-mediated therapy of inflammatory bowel disease","volume":"14","author":"Wang","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.jconrel.2026.115218_bb0165","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijpharm.2016.05.043","article-title":"Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model","volume":"509","author":"Watanabe","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115218_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.matt.2025.102249","article-title":"Stimuli-responsive nanomaterials for targeted drug delivery in inflammatory bowel disease: advances and emerging directions","volume":"8","author":"Huang","year":"2025","journal-title":"Matter"},{"key":"10.1016\/j.jconrel.2026.115218_bb0175","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1186\/s12951-025-03753-9","article-title":"pH-responsive Oral liposomal delivery of hydrogen sulfide donor GYY4137 enables colon-targeted therapy for inflammatory bowel disease","volume":"23","author":"Oh","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0180","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/17425247.2011.574121","article-title":"Polysaccharides: a targeting strategy for colonic drug delivery","volume":"8","author":"Shah","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0185","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/pharmaceutics17050547","article-title":"Oral lipid nanoparticles for improving the efficiency of drug delivery systems in ulcerative colitis: recent advances and future prospects","volume":"17","author":"Zhu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115218_bb0190","article-title":"Accelerating diabetic wound healing by ROS-scavenging lipid nanoparticle-mRNA formulation","volume":"121","author":"Wang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115218_bb0195","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3390\/pharmaceutics17101315","article-title":"Translational advances in lipid nanoparticle drug delivery systems for cancer therapy: current status and future horizons","volume":"17","author":"Rachamala","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115218_bb0200","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1128\/MCB.00228-12","article-title":"LRP-1--CD44, a new cell surface complex regulating tumor cell adhesion","volume":"32","author":"Perrot","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0205","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ibd\/izy123","article-title":"Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis","volume":"24","author":"Zhang","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115218_bb0210","doi-asserted-by":"crossref","DOI":"10.1177\/20417314241265892","article-title":"Oral delivery of pH-sensitive nanoparticles loaded Celastrol targeting the inflammatory colons to treat ulcerative colitis","volume":"15","author":"Zhao","year":"2024","journal-title":"J. Tissue Eng."},{"key":"10.1016\/j.jconrel.2026.115218_bb0215","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.2174\/1381612827666210617120302","article-title":"An overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis","volume":"27","author":"Alfagih","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2026.115218_bb0220","series-title":"Lipidology","first-page":"19","article-title":"The crosstalk between non-coding RNAs and lipid metabolism in chronic disease progression","author":"Zayani","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115218_bb0225","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejps.2018.10.009","article-title":"Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-a siRNA provide a novel strategy for the experimental treatment of ulcerative colitis","volume":"125","author":"Huang","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115218_bb0230","doi-asserted-by":"crossref","first-page":"eadf3887","DOI":"10.1126\/sciadv.adf3887","article-title":"Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota-brain interactions in colitis","volume":"9","author":"He","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0235","doi-asserted-by":"crossref","first-page":"28242","DOI":"10.1021\/acsnano.5c05032","article-title":"A colon-targeted oral nanosystem disrupts the inflammatory loop in enteric glia to alleviate ulcerative colitis","volume":"19","author":"Zhang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115218_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/nano14221800","article-title":"Harnessing a safe novel lipid nanoparticle: targeted oral delivery to colonic epithelial and macrophage cells in a colitis mouse model","volume":"14","author":"Mow","year":"2024","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.jconrel.2026.115218_bb0245","doi-asserted-by":"crossref","first-page":"25657","DOI":"10.1021\/acsnano.4c07750","article-title":"Oral microto-Nano genome-editing system enabling targeted delivery and conditional activation of CRISPR-Cas9 for gene therapy of inflammatory bowel disease","volume":"18","author":"Lin","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115218_bb0250","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/pharmaceutics12010068","article-title":"Strategic approaches for Colon targeted drug delivery: an overview of recent advancements","volume":"12","author":"Lee","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115218_bb0255","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/1756283X17709974","article-title":"MMX((R)) technology and its applications in gastrointestinal diseases","volume":"10","author":"Nardelli","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0260","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MOG.0000000000001064","article-title":"Advances in colon-targeted drug technologies","volume":"41","author":"Yeung","year":"2025","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0265","doi-asserted-by":"crossref","first-page":"10893","DOI":"10.1038\/s41467-024-55263-1","article-title":"Colon-targeted engineered postbiotics nanoparticles alleviate osteoporosis through the gut-bone axis","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115218_bb0270","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.2147\/IJN.S390102","article-title":"Advancement in therapeutic intervention of prebiotic-based nanoparticles for colonic diseases","volume":"17","author":"Ren","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115218_bb0275","article-title":"A new paradigm for precision drug delivery in inflammatory bowel disease: effective transfer, enhanced retention, and pathology-targeting treatment via biomaterials and engineered platforms","volume":"4","author":"Gan","year":"2025","journal-title":"MedComm \u2013 Biomater. Appl."},{"key":"10.1016\/j.jconrel.2026.115218_bb0280","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/md20050335","article-title":"Multiple roles of chitosan in mucosal drug delivery: an updated review","volume":"20","author":"Mura","year":"2022","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.jconrel.2026.115218_bb0285","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3390\/polym17121640","article-title":"A review on the recent advancements of polymer-modified mesoporous silica nanoparticles for drug delivery under stimuli-trigger","volume":"17","author":"Santhamoorthy","year":"2025","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115218_bb0290","first-page":"393","article-title":"Revolutionizing neural regeneration with smart responsive materials: current insights and future prospects","volume":"52","author":"Gao","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2026.115218_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119379","article-title":"A dual pH and microbiota-triggered coating (Phloral) for fail-safe colonic drug release","volume":"583","author":"Varum","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115218_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119372","article-title":"OPTICORE, an innovative and accurate colonic targeting technology","volume":"583","author":"Varum","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115218_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/bip.23336","article-title":"Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting","volume":"111","author":"Bertoni","year":"2020","journal-title":"Biopolymers"},{"key":"10.1016\/j.jconrel.2026.115218_bb0310","first-page":"101","article-title":"ROS-responsive drug delivery systems for biomedical applications, Asian","volume":"13","author":"Tao","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115218_bb0315","article-title":"A sequential release micro-nano system for colitis therapy via gut microbiota and immune regulation","volume":"64","author":"Zhu","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2026.115218_bb0320","series-title":"Gels","article-title":"Designing of pH-sensitive hydrogels for colon targeted drug delivery; characterization and in vitro evaluation","author":"Suhail","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115218_bb0325","doi-asserted-by":"crossref","first-page":"28827","DOI":"10.1021\/acsomega.4c03240","article-title":"pH-sensitive hydrogels fabricated with hyaluronic acid as a polymer for site-specific delivery of Mesalamine","volume":"9","author":"Liaqat","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2026.115218_bb0330","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11095-021-02993-2","article-title":"Research on preparation of 5-ASA colon-specific hydrogel delivery system without crosslinking agent by Mechanochemical method","volume":"38","author":"Xu","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115218_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213735","article-title":"Dual stimuli-responsive delivery system for self-regulated colon-targeted delivery of poorly water-soluble drugs","volume":"157","author":"Rabeh","year":"2024","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0340","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1080\/10717544.2021.1934189","article-title":"An efficient enzyme-triggered controlled release system for colon-targeted oral delivery to combat dextran sodium sulfate (DSS)-induced colitis in mice","volume":"28","author":"Li","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0345","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.actbio.2024.07.054","article-title":"Matrix metalloproteinase-responsive hydrogels with tunable retention for on-demand therapy of inflammatory bowel disease","volume":"186","author":"Xie","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115218_bb0350","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ijbiomac.2022.09.247","article-title":"ROS-responsive hyaluronic acid hydrogel for targeted delivery of probiotics to relieve colitis","volume":"222","author":"Huang","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.133855","article-title":"Redox-sensitive hydrogel based on hyaluronic acid with selenocystamine cross-linking for the delivery of Limosilactobacillus reuteri in a DSS-induced colitis mouse model","volume":"276","author":"Lu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0360","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.actbio.2024.06.021","article-title":"Hydrogel-forming viscous liquid in response to ROS restores the gut mucosal barrier of colitis mice via regulating oxidative redox homeostasis","volume":"184","author":"Shangguan","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115218_bb0365","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.ijbiomac.2020.11.117","article-title":"Carboxymethyl chitosan microspheres loaded hyaluronic acid\/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease","volume":"167","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.123206","article-title":"Functional chitosan\/HP-\u03b2-CD hydrogel for targeted co-delivery of rhubarb-derived nanovesicles and kaempferol for alleviating ulcerative colitis","volume":"352","author":"Tang","year":"2025","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2026.115218_bb0375","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2165\/00003088-197601060-00002","article-title":"Clinical pharmacokinetics of Sulphasalazine","volume":"1","author":"Das","year":"1976","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.115218_bb0380","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/gut.30.5.675","article-title":"Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study","volume":"30","author":"Rao","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115218_bb0385","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0016-5085(98)70627-4","article-title":"Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis","volume":"114","author":"Green","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115218_bb0390","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/jps.21404","article-title":"N,N\u2019-Bis(5-aminosalicyl)-L-cystine is a potential colon-specific 5-aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis","volume":"98","author":"Kim","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115218_bb0395","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1023\/A:1015838825437","article-title":"Colon-specific delivery of dexamethasone from a glucoside prodrug in the Guinea pig","volume":"8","author":"Tozer","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115218_bb0400","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.adk7633","article-title":"Bespoke plant glycoconjugates for gut microbiota\u2013mediated drug targeting","volume":"388","author":"Ma","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115218_bb0405","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gut.35.10.1439","article-title":"A budesonide prodrug accelerates treatment of colitis in rats","volume":"35","author":"Cui","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115218_bb0410","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.3748\/wjg.v11.i47.7457","article-title":"Colon-specific drug delivery systems based on cyclodextrin prodrugs: in vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates","volume":"11","author":"Zou","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0415","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1021\/acs.jmedchem.1c02166","article-title":"Discovery of a colon-targeted azo prodrug of Tofacitinib through the establishment of colon-specific delivery systems constructed by 5-ASA\u2013PABA\u2013MAC and 5-ASA\u2013PABA\u2013diamine for the treatment of ulcerative colitis","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115218_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106911","article-title":"State-of-the-art and future perspectives in ingestible remotely controlled smart capsules for drug delivery: a GENEGUT review","volume":"203","author":"Hoffmann","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115218_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.device.2024.100438","article-title":"Magnetically triggered ingestible capsule for localized microneedle drug delivery","volume":"2","author":"Levy","year":"2024","journal-title":"Device"},{"key":"10.1016\/j.jconrel.2026.115218_bb0430","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/bdd.1824","article-title":"Regional gastrointestinal delivery of remogliflozin etabonate in humans","volume":"34","author":"O\u2019Connor-Semmes","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jconrel.2026.115218_bb0435","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.gie.2013.03.170","article-title":"A novel ingestible electronic drug delivery and monitoring device","volume":"78","author":"van der Schaar","year":"2013","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.jconrel.2026.115218_bb0440","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwaf400","article-title":"Multichamber magnetic capsule robot for selective liquid sampling and drug delivery","volume":"12","author":"Wu","year":"2025","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.jconrel.2026.115218_bb0445","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41467-024-46046-9","article-title":"Magnetically driven capsules with multimodal response and multifunctionality for biomedical applications","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115218_bb0450","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apt.17844","article-title":"Review article: current status and future directions of ingestible electronic devices in gastroenterology","volume":"59","author":"Thwaites","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.115218_bb0455","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade5041","article-title":"Milk-derived extracellular vesicles protect intestinal barrier integrity in the gut-liver axis","volume":"9","author":"Tong","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0460","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.7150\/thno.73650","article-title":"Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis","volume":"12","author":"Gao","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115218_bb0465","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202153365","article-title":"Exosome-like nanoparticles from mulberry bark prevent DSS-induced colitis via the AhR\/COPS8 pathway, the","volume":"23","author":"Sriwastva","year":"2022","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jconrel.2026.115218_bb0470","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12462","article-title":"Milk-derived extracellular vesicles functionalized with anti-tumour necrosis factor-\u03b1 nanobody and anti-microbial peptide alleviate ulcerative colitis in mice","volume":"13","author":"Jing","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.jconrel.2026.115218_bb0475","doi-asserted-by":"crossref","first-page":"53460","DOI":"10.1021\/acsami.4c10562","article-title":"Functional ginger-derived extracellular vesicles-coated ZIF-8 containing TNF-\u03b1 siRNA for ulcerative colitis therapy by modulating gut microbiota","volume":"16","author":"Cui","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.115218_bb0480","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jconrel.2024.07.035","article-title":"Application of 3D printing on the design and development of pharmaceutical oral dosage forms","volume":"373","author":"Paccione","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115218_bb0485","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/bp070462h","article-title":"Current perspectives on stability of protein drug products during formulation, fill and finish operations","volume":"24","author":"Rathore","year":"2008","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.jconrel.2026.115218_bb0490","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1021\/acs.molpharmaceut.8b01118","article-title":"Developing biologics tablets: the effects of compression on the structure and stability of bovine serum albumin and lysozyme","volume":"16","author":"Wei","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115218_bb0495","article-title":"Animal models of inflammatory bowel disease: category and evaluation indexes","volume":"12","author":"Wen","year":"2024","journal-title":"Gastroenterol. Report"},{"key":"10.1016\/j.jconrel.2026.115218_bb0500","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jconrel.2026.115218_bb0505","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.60.1.0008","article-title":"Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments","volume":"60","author":"McConnell","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0510","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/jps.24365","article-title":"Animal farm: considerations in animal gastrointestinal physiology and relevance to drug delivery in humans","volume":"104","author":"Hatton","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115218_bb0515","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mrm.10207","article-title":"Gastrointestinal transit times in mice and humans measured with 27Al and 19F nuclear magnetic resonance","volume":"48","author":"Schwarz","year":"2002","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.jconrel.2026.115218_bb0520","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/ibd\/izad312","article-title":"Unveiling colitis: a journey through the dextran sodium sulfate-induced model","volume":"30","author":"Yang","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115218_bb0525","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/intimm\/5.11.1461","article-title":"Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice","volume":"5","author":"Powrie","year":"1993","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0530","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000000287","article-title":"Animal models of inflammatory bowel disease: how useful are they really?","volume":"32","author":"Kolios","year":"2016","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0535","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1016\/j.cell.2025.04.014","article-title":"Global genetic diversity of human gut microbiome species is related to geographic location and host health","volume":"188","author":"Andreu-S\u00e1nchez","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115218_bb0540","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nutres.2020.03.005","article-title":"Human gut microbiome composition and tryptophan metabolites were changed differently by fast food and Mediterranean diet in 4 days: a pilot study","volume":"77","author":"Zhu","year":"2020","journal-title":"Nutr. Res."},{"key":"10.1016\/j.jconrel.2026.115218_bb0545","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00290","article-title":"Mucosal interactions between genetics, diet, and microbiome in inflammatory bowel disease","volume":"7","author":"Basson","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0550","series-title":"Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic Therapy","author":"National Library of Medicine (US)","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115218_bb0555","series-title":"A Randomised, Double-blind, Double-dummy, Multicentre, Phase III, Non Inferiority Trial of an Oral Mesalazine Formulation in Patients With Active Mild to Moderate Ulcerative Colitis for the Induction of Remission","author":"National Library of Medicine (US)","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115218_bb0560","series-title":"Rimegepant, a CGRP Antagonist, in the Treatment of Visceral Sensation and Chronic Abdominal Pain: A Pilot Study","author":"National Library of Medicine (US)","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115218_bb0565","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","article-title":"Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?","volume":"23","author":"Vasudevan","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0570","series-title":"Center for Drug Evaluation and Research (Ed.)","article-title":"Bioavailability studies submitted in NDAs or INDs \u2014 general considerations","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115218_bb0575","series-title":"Committee for Medicinal Products for Human Use (CHMP)","article-title":"Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract - Revision 1","author":"European Medicines Agencies","year":"2018"},{"key":"10.1016\/j.jconrel.2026.115218_bb0580","series-title":"U.S. Food and Drug Administration","article-title":"Draft guidance on mesalamine delayed release tablet","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115218_bb0585","series-title":"U.S. Food and Drug Administration","article-title":"Draft guidance on mesalamine extended release capsule","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.jconrel.2026.115218_bb0590","series-title":"Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER)","article-title":"Guidance for industry: ulcerative colitis: developing drugs for treatment","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115218_bb0595","series-title":"Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER)","article-title":"Guidance for industry: Crohn\u2019s disease: Developing drugs for treatment","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115218_bb0600","series-title":"Center for Drug Evaluation and Research (CDER), Center for Drug Evaluation and Research (CDER)","article-title":"Dissolution testing and acceptance criteria for immediate-release solid oral dosage form drug products containing high solubility drug substances","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.jconrel.2026.115218_bb0605","series-title":"Committee for Medicinal Products for Human Use (CHMP)","article-title":"Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms","author":"European Medicinal Agencies","year":"2014"},{"key":"10.1016\/j.jconrel.2026.115218_bb0610","series-title":"Progress in Molecular Biology and Translational Science","first-page":"385","article-title":"Chapter eleven - advancements in wearable electrochemical biosensors: The next generation of insulin detection devices","author":"Moonla","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115218_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioelechem.2024.108830","article-title":"Inside out: exploring edible biocatalytic biosensors for health monitoring","volume":"161","author":"Marchian\u00f2","year":"2025","journal-title":"Bioelectrochemistry"},{"key":"10.1016\/j.jconrel.2026.115218_bb0620","series-title":"Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information, in: C.f.B.E.a.R. (CBER) (Ed.)","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.jconrel.2026.115218_bb0625","article-title":"3D printed spiral tube-like cellulose scaffold for oral delivery of probiotics","volume":"10","author":"Zhang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107252","article-title":"In vitro\/in vivo evaluation of 3D bioprinted silk fibroin hydrogels for IBD: a dual mesalazine and TNF-\u03b1 siRNA approach","volume":"213","author":"Y\u0131ld\u0131z","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115218_bb0635","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s13346-025-01932-7","article-title":"3D-printed core-shell tablet for effective oral delivery of AT-MSC secretome in inflammatory bowel disease therapy","volume":"16","author":"Munoz-Perez","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.115218_bb0640","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molmed.2024.12.005","article-title":"Probiotics in inflammatory bowel disease: microbial modulation and therapeutic prospects","volume":"31","author":"Vallejos","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115218_bb0645","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1038\/s41467-022-31171-0","article-title":"Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115218_bb0650","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejpb.2009.11.008","article-title":"A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract","volume":"74","author":"Liu","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115218_bb0655","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.actbio.2023.05.050","article-title":"Three generations of thiolated cyclodextrins: a direct comparison of their mucus permeating and mucoadhesive properties","volume":"167","author":"Haddadzadegan","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115218_bb0660","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1021\/acs.biomac.3c00577","article-title":"Thiolated cellulose: a dual-acting Mucoadhesive and permeation-enhancing polymer","volume":"24","author":"Kali","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.115218_bb0665","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/jfb16120456","article-title":"3D-printed multifunctional multicompartment polymer-based capsules for tunable and spatially controlled drug release","volume":"16","author":"Minopoli","year":"2025","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.jconrel.2026.115218_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107277","article-title":"Next generation capsules: emerging technologies in capsule fabrication and targeted oral drug delivery","volume":"214","author":"Millet","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115218_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213576","article-title":"Primary human hepatocytes-laden scaffolds for the treatment of acute liver failure","volume":"153","author":"Rodriguez-Fernandez","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2026.115218_bb0680","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/17474124.2021.1840351","article-title":"Capsule endoscopy - recent developments and future directions","volume":"15","author":"Chetcuti Zammit","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0685","first-page":"103","article-title":"Ingestible sensors and medication adherence: focus on use in serious mental illness","volume":"8","author":"Alipour","year":"2020","journal-title":"Pharmacy (Basel, Switzerland)"},{"key":"10.1016\/j.jconrel.2026.115218_bb0690","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41578-018-0070-3","article-title":"Ingestible electronics for diagnostics and therapy","volume":"4","author":"Steiger","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.115218_bb0695","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1109\/TBME.2023.3343337","article-title":"Smart capsule for targeted detection of inflammation levels inside the GI tract","volume":"71","author":"Kadian","year":"2024","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115218_bb0700","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.actbio.2022.09.050","article-title":"Smart capsule for targeted proximal colon microbiome sampling","volume":"154","author":"Nejati","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115218_bb0705","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s42826-022-00128-1","article-title":"Role of animal models in biomedical research: a review","volume":"38","author":"Mukherjee","year":"2022","journal-title":"Lab. Anim. Research"},{"key":"10.1016\/j.jconrel.2026.115218_bb0710","series-title":"Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs, in, April 10","author":"FDA","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115218_bb0715","series-title":"NIH Establishes Nation's First Dedicated Organoid Development Center to Reduce Reliance on Animal Modeling","year":"2025"},{"key":"10.1016\/j.jconrel.2026.115218_bb0720","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1208\/s12248-023-00862-x","article-title":"Applications of modeling and simulation approaches in support of drug product development of oral dosage forms and locally acting drug products: a symposium summary","volume":"25","author":"Tsakalozou","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.115218_bb0725","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s12015-025-10894-9","article-title":"Latest advanced techniques for improving intestinal organoids limitations","volume":"21","author":"Tonini","year":"2025","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.jconrel.2026.115218_bb0730","doi-asserted-by":"crossref","DOI":"10.1177\/20417314251319475","article-title":"Strategies to overcome the limitations of current organoid technology - engineered organoids","volume":"16","author":"Fan","year":"2025","journal-title":"J. Tissue Eng."},{"key":"10.1016\/j.jconrel.2026.115218_bb0735","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41525-018-0067-2","article-title":"FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine","volume":"3","author":"Luh","year":"2018","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.jconrel.2026.115218_bb0740","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13046-018-0702-x","article-title":"Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations","volume":"37","author":"Allegretti","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115218_bb0745","doi-asserted-by":"crossref","first-page":"10291","DOI":"10.1038\/s41467-024-54797-8","article-title":"Multi-biome analysis identifies distinct gut microbial signatures and their crosstalk in ulcerative colitis and Crohn\u2019s disease","volume":"15","author":"Akiyama","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115218_bb0750","doi-asserted-by":"crossref","DOI":"10.4291\/wjgp.v16.i4.112961","article-title":"Gut microbiota as a potential predictor of therapeutic response in adults with Crohn\u2019s disease: a systematic review","volume":"16","author":"Dutta","year":"2025","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"10.1016\/j.jconrel.2026.115218_bb0755","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.jcyt.2025.03.226","article-title":"GMP implementation of long-read technology next generation sequencing for the QC testing of cell and gene therapy products","volume":"27","author":"Fasching","year":"2025","journal-title":"Cytotherapy"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600622X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600622X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:59:53Z","timestamp":1790211593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592600622X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":151,"alternative-id":["S016836592600622X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115218","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation colon-targeted oral delivery for immune modulation in inflammatory bowel diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115218"}}